A prospective, observational, single arm, multi-site, pilot study of Atezolizumab in non-ocogene addicted advanced NSCLC with PD-L1 TPS ≥50%, with longitudinal assessment of C-FLIP expression of monocytic myeloid-derived suppressor cells

Copyright © 2025 Informapro S.R.L. - TUTTI I DIRITTI RISERVATI
per contatti riguardanti lo Studio Flip-Immuno flip-immuno@ipro-it.eu